Cardiff Oncology, Inc.
CRDF Nasdaq
SEC CIK 1213037
Follow Cardiff Oncology
Weekly email: filings, results
Revenue, last quarter
$171K
+42.5% vs same quarter last year
Net income
−$8.9M
+21.3% vs same quarter last year
EPS, diluted
−$0.12
+29.4% vs same quarter last year
Operating cash flow
−$9.9M
+8.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $593K | −$45.9K |
| FY24 | $683K | −$45.4K |
| FY23 | $488K | −$41.4K |
| FY22 | $386K | −$38.7M |
| FY21 | $359K | −$28.3M |
| FY20 | $366K | −$19.3M |
| FY19 | $244.6K | −$16.4M |
| FY18 | $378.3K | −$16.5M |
| FY17 | $505.4K | −$24.9M |
| FY16 | $381.1K | −$39.2M |
| FY15 | $312.8K | −$27.5M |
| FY14 | $280.2K | −$14.3M |
| FY13 | $259.2K | −$11.8M |
| FY12 | $450.4K | −$11.6M |
| FY11 | $257.7K | −$2.2M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | −8256.3% | −7.7% |
| FY24 | - | −7123.1% | −6.7% |
| FY23 | - | −9305.7% | −8.5% |
| FY22 | - | −10337.3% | −10026.9% |
| FY21 | - | −8037.6% | −7880.5% |
| FY20 | - | −5214.8% | −5275.1% |
| FY19 | 100% | −6817.8% | −6709.7% |
| FY18 | −57.9% | −4507.6% | −4351.1% |
| FY17 | - | −5064.4% | −4928.1% |
| FY16 | - | −10534.9% | −10287.7% |
| FY15 | −101.1% | −8079.5% | −8782% |
| FY14 | 94.5% | −5334.2% | −5113% |
| FY13 | - | −4123.7% | −4555.9% |
| FY12 | - | −1076.6% | −2567.9% |
| FY11 | - | −1155.2% | −868.9% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$38M |
| FY24 | −$37.8M |
| FY23 | −$31.5M |
| FY22 | −$34.8M |
| FY21 | −$23.2M |
| FY20 | −$16.5M |
| FY19 | −$13.3M |
| FY18 | −$13.2M |
| FY17 | −$23.4M |
| FY16 | −$31.9M |
| FY15 | −$24.4M |
| FY14 | −$13.1M |
| FY13 | −$8M |
| FY12 | −$5.2M |
| FY11 | −$1.9M |
- Cardiff Oncology
- Healthcare median
Show the numbers
| Year | Cardiff Oncology | Healthcare median |
|---|---|---|
| FY25 | −7.7% | −30.6% |
| FY24 | −6.7% | −47% |
| FY23 | −8.5% | −58% |
| FY22 | −10026.9% | −80.4% |
| FY21 | −7880.5% | −71.8% |
| FY20 | −5275.1% | −62.2% |
| FY19 | −6709.7% | −46.2% |
| FY18 | −4351.1% | −49.6% |
| FY17 | −4928.1% | −45.9% |
| FY16 | −10287.7% | −36% |
| FY15 | −8782% | −37.8% |
| FY14 | −5113% | −35.5% |
| FY13 | −4555.9% | −37.1% |
| FY12 | −2567.9% | −29.1% |
| FY11 | −868.9% | −27.9% |